Patients experienced a median 57.6-month delay from first symptoms to ATTR-CM diagnosis, study finds.
Heart Failure
Advertisement
MITT and safety data show acoramidis significantly lowers AFib-related events in transthyretin cardiac amyloidosis.
LuX-Valve offers a safe, effective option for severe TR patients at high surgical risk.
ESC 2025: Acoramidis may reduce AF/flutter burden in ATTR-CM, per new ATTRibute-CM trial analysis discussed by CardioNerds.
PVR severity is linked to higher short-term mortality in HFrEF, highlighting its role in risk stratification.
IMPLEMENT-HF raised heart failure quad therapy use from 4.7% to 44.6% at discharge and 0% to 44.8% at 30 days.
Experts call for better trials and teamwork to advance transcatheter valve treatment for heart failure-related valve disease.
Expert Interviews
Cardio Care Today delivers the latest medical industry news, giving health care professionals the curated content most relevant to their fields and practices.
Get the latest medical updates and insights straight to your inbox.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.